908 Devices IncMASS
▲ PositiveCapitalrelevance
Q2 revenue up 23%, EBITDA loss narrowed, guidance raised
Impact on assets 1
Biotech & Genomic Medicine
908 Devices Inc908 Devices Reports 23% Revenue Growth in Q2 2026
2▲1 ▼0Impact / 5
908 Devices reported second quarter 2026 revenue of $16.1 million, a 23% increase year-over-year, driven by strong demand from U.S. state and local customers and the recent acquisition of NIRLAB. The company shipped 198 devices in the quarter, bringing its installed base to 4,101, and its adjusted EBITDA loss narrowed by more than 50% to $1.9 million. Management raised the low end of its full-year revenue guidance to a range of $68 million to $70 million, representing growth of 21% to 25%, and highlighted a $6 million ProtectIR order from an Asia Pacific corrections agency secured in July. The company also noted progress with its VipIR FTIR device, shipping more than 35 units in the quarter, and expects to exceed 100 VipIR shipments for the year.
908 Devices IncQ2 revenue up 23%, EBITDA loss narrowed, guidance raised